Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1196 of 1,196 matching trials from the live ClinicalTrials.gov search.

Filters: Durham, North Carolina Clear all

Conditions: Hepatitis B
Interventions: Entecavir and peginterferon; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 20
States / cities: Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Liposome-encapsulated Daunorubicin-Cytarabine, Multigated Acquisition Scan, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 59 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 216
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 175 more

Conditions: Pulmonary Arterial Hypertension
Interventions: observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 75
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 0 Years to 15 Years
Enrollment: 3,031 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2003
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, Crizotinib, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2036
U.S. locations: 1613
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more

Conditions: Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions: Zanzalintinib, Everolimus; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 18 Years
Enrollment: 630 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 29 more

Conditions: Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cytarabine, Daunorubicin Hydrochloride, Idarubicin, Laboratory Biomarker Analysis, Vorinostat; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 441
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 302 more

Conditions: Physical Activity
Interventions: Your Move (physical activity), Your Money (financial empowerment); Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Male only
Enrollment: 628 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Heart Failure With Left Bundle Branch Block
Interventions: aCRT ON, aCRT OFF; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 3,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 90
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 76 more

Conditions: Cardiac Resynchronization Therapy
Interventions: ACUITY X4 quadripolar coronary venous lead and RELIANCE 4-FRONT defibrillation lead; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 2,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 96
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 85 more

Conditions: Essential Thrombocythemia
Interventions: Ropeginterferon alfa-2b-njft (P1101); Drug
Lead sponsor: PharmaEssentia; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 30
States / cities: Birmingham, Alabama • Duarte, California • Greenbrae, California + 25 more

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Interventions: Survodutide, Placebo; Combination Product
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 165
States / cities: Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 132 more

Conditions: Lung Diseases, Bronchopulmonary Dysplasia
Interventions: iNO, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 1 Year
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 14
States / cities: Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 11 more

Conditions: Related Hematopoietic Stem Cell Donors
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 1,812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 52
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more

Conditions: Obesity
Interventions: Baby NAP SACC, Back to Sleep; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Months and older
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Hypertension
Interventions: ramipril, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 39
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Simtuzumab, Simtuzumab placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 136
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more

Conditions: Solid Tumor, Soft Tissue Sarcoma, Metastatic Sarcoma, Sarcoma
Interventions: NC 6300; Drug
Lead sponsor: NanoCarrier Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Duarte, California • Santa Monica, California • Las Vegas, Nevada + 3 more

Search by objective public record fields.

Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

A Blood Test to Look at Cells of the Immune System in Healthy Children

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

FITShop: Promoting Physical Activity in Black Barbershops

AdaptResponse Clinical Trial

Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants

Stem Cell Related Donor Safety Study

Baby Nutrition and Physical Activity Self-Assessment for Child Care (NAP SACC) Intervention Study

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma